Effect of berberine on irritable bowel syndrome: A symptom-based review

Abstract

Phytotherapeutic applications have gained a place in the symptomatic treatment of irritable bowel syndrome, one of the most common diseases globally among functional bowel diseases. This study aimed to compile evidence regarding the efficacy of berberine in relieving the symptoms of irritable bowel syndrome. In this review, the electronic databases of PubMed, Google Scholar, MEDLINE, and Web of Science were used, and current publications were searched without any language restrictions. The screening was performed by first performing a general search using the keyword "berberine and irritable bowel syndrome", followed by individual searches for each symptom. Although there are many preclinical studies investigating the effect of berberine on the gastrointestinal tract, human studies are still limited. Studies show that berberine may positively affect abdominal pain, diarrhea, inflammation, microbiota, and visceral hypersensitivity, although the mechanisms of action are not yet clear. However, available data suggest that the therapeutic use of berberine in irritable bowel syndrome may be limited to the predominant type of diarrhea and selected patients whose symptoms are evaluated individually. Evidence presented in this paper needs to be further supported by human clinical studies.

Keywords

• Diarrhea
• Abdominal pain
• Motility
• Phytotherapy

Kaynakça

1. Akyuz, F., 2016. İrritabl Barsak Sendromu. Güncel Gastroenteroloji Dergisi; 20(4), 415-420.
2. Can, G., Yılmaz, B., 2015. İrritabl bağırsak sendromunun tanı ve tedavisinde yaklaşımlar. Güncel Gastroenteroloji Dergisi, 19(3), 181-191.
3. Čerňáková, M., Košťálová, D., 2002. Antimicrobial activity of berberine—A constituent ofMahonia aquifolium. Folia Microbiologica, 47(4), 375-378.
4. Chen, C., Lu, M., Pan, Q., Fichna, J., Zheng, L., Wang, K., Kreis, M., 2015a. Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One, 10(12), e0145556.
5. Chen, C., Tao, C., Liu, Z., Lu, M., Pan, Q., 2015b. A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytotherapy Research, 29(11), 1822-1827.
6. Chen, Y.X., Gao, Q.Y., Zou, T.H., Wang, B.M., Liu, S.D., Sheng, J.Q., Fang, J.Y., 2020. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. The Lancet Gastroenterology & Hepatology, 5(3), 267-275.
7. Chey, W.D., Lembo, A.J., Lavins, B.J., Shiff, S.J., Kurtz, C.B., Currie, M.G., Johnston, J.M., 2012. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Official Journal of the American College of Gastroenterology | ACG, 107(11), 1702-1712.
8. Clavé, P., Acalovschi, M., Triantafillidis, J.K., Uspensky, Y.P., Kalayci, C., Shee, V., OBIS Study Investigators., 2011. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 34(4), 432-442.

9. Delzenne, N.M, Bindels, B., 2019. Food for thought about manipulating gut bacteria. Nature, 577(7788), 32-34.
10. Di Pierro, F., Bertuccioli, A., Giuberti, R., Saponara, M., Ivaldi, L., 2020. Role of a berberine-based nutritional supplement in reducing diarrhea in subjects with functional gastrointestinal disorders. Minerva Gastroenterologica e Dietologica, 66(1), 29-34.
11. Drossman, D.A., Chey, W.D., Johanson, J.F., Fass, R., Scott, C., Panas, R., Ueno, R., 2009. Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome–results of two randomized, placebo‐controlled studies. Alimentary Pharmacology & Therapeutics, 29(3), 329-341.
12. Feng, A.W., Gao, W., Zhou, G.R., Yu, R., Li, N., Huang, X.L., Li, J.S., 2012. Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPARγ pathway during acute endotoxemia. International Immunopharmacology, 12(1), 182-188.
13. Feng, Y., Li, Y., Chen, C., Lin, X., Yang, Y., Cai, H., Jia, Y., 2013. Inhibiting roles of berberine in gut movement of rodents are related to activation of the endogenous opioid system. Phytotherapy Research, 27(10), 1564-1571.
14. Gu, L., Li, N., Li, Q., Zhang, Q., Wang, C., Zhu, W., Li, J. (2009). The effect of berberine in vitro on tight junctions in human Caco-2 intestinal epithelial cells. Fitoterapia, 80(4), 241-248.
15. Habtemariam, S., 2020. Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacological Research, 155, 104722.
16. Hu, Y., Chen, X., Duan, H., Hu, Y., Mu, X., 2009. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells. Immunopharmacology and Immunotoxicology, 31(4), 550-555.
17. Inadomi, J.M., Fennerty, M.B., Bjorkman, D., 2003. The economic impact of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 18(7), 671-682.
18. Jeong, H.W., Hsu, K.C., Lee, J.W., Ham, M., Huh, J.Y., Shin, H.J., Kim, J.B., 2009. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism, 296(4), E955-E964.
19. Jia, Q., Zhang, L., Zhang, J., Pei, F., Zhu, S., Sun, Q., Duan, L., 2019. Fecal microbiota of diarrhea-predominant irritable bowel syndrome patients causes hepatic inflammation of germ-free rats and berberine reverses it partially. BioMed Research International, 2019, 4530203.
20. Khan, S., Chang, L., 2010. Diagnosis and management of IBS. Nature Reviews Gastroenterology & Hepatology, 7(10), 565-581.
21. Khin, M.U., Myo, K., Nyunt, N.W., Aye, K., Tin, U., 1985. Clinical trial of berberine in acute watery diarrhoea. British Medical Journal (Clinical Research Ed.), 291(6509), 1601-1605.
22. Kidd, P.M., 2009. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Alternative Medicine Review, 14(3), 226-246.
23. Kim, H.J., 2015. Berberine ameliorates allodynia induced by chronic constriction injury of the sciatic nerve in rats. Journal of Medicinal Food, 18(8), 909-915.
24. Kulkarni, S.K., Dhir, A., 2010. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 24(3), 317-324.
25. Langmead, L., Chitnis, M., Rampton, D.S., 2002. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflammatory Bowel Diseases, 8(3), 174-179.
26. Liang, Y., Xu, X., Yin, M., Zhang, Y., Huang, L., Chen, R., Ni, J., 2019. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocrine Journal, 66(1), 51-63.
27. Longstreth, G.F., Thompson, W.G., Chey, W.D., Houghton, L.A., Mearin, F., Spiller, R.C., 2006. Functional bowel disorders. Gastroenterology, 130(5), 1480-1491.
28. Longstreth, G.F., Wilson, A., Knight, K., Wong, J., Chiou, C.F., Barghout, V., Ofman, J.J., 2003. Irritable bowel syndrome, health care use, and costs: a US managed care perspective. The American Journal of Gastroenterology, 98(3), 600-607.
29. Lovell, R.M., & Ford, A.C., 2012. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical Gastroenterology and Hepatology, 10(7), 712-721.
30. Mansueto, P., Seidita, A., D'Alcamo, A., Carroccio, A., 2015. Role of FODMAPs in patients with irritable bowel syndrome. Nutrition in Clinical Practice, 30(5), 665-682.
31. Ooi, S.L., Correa, D., Pak, S.C., 2019. Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome–What is the current evidence?. Complementary Therapies in Medicine, 43, 73-80.
32. Palsson, O.S., Whitehead, W.E., 2013. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. Clinical Gastroenterology and Hepatology, 11(3), 208-216.
33. Payne, A., Blanchard, E.B., 1995. A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. Journal of Consulting and Clinical Psychology, 63(5), 779-786.
34. Rabbani, G.H., Butler, T., Knight, J., Sanyal, S.C., Alam, K., 1987. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. Journal of Infectious Diseases, 155(5), 979-984.
35. Round, J.L., Mazmanian, S.K., 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews Immunology, 9(5), 313-323.
36. Saha, P., Bhattacharjee, S., Sarkar, A., Manna, A., Majumder, S., Chatterjee, M., 2011. Berberine chloride mediates its anti-leishmanial activity via differential regulation of the mitogen activated protein kinase pathway in macrophages. PLoS One, 6(4), e18467.
37. Scalbert, A., Williamson, G., 2000. Dietary intake and bioavailability of polyphenols. The Journal of Nutrition, 130(8), 2073S-2085S.
38. Schmulson, M.J., Drossman, D.A., 2017. What is new in Rome IV. Journal of Neurogastroenterology and Motility, 23(2), 151-163.
39. Soares, R.L., 2014. Irritable bowel syndrome: a clinical review. World Journal of Gastroenterology: WJG, 20(34), 12144-12160.
40. Sun, D., Abraham, S.N., Beachey, E.H., 1988. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrobial Agents and Chemotherapy, 32(8), 1274-1277.
41. Sun, S., Wang, K., Lei, H., Li, L., Tu, M., Zeng, S., Jiang, H., 2014. Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 49, 1-6.
42. Talley, N.J., Spiller, R., 2002. Irritable bowel syndrome: a little understood organic bowel disease?. The Lancet, 360(9332), 555-564.
43. Tang, Q.L., Lai, M.L., Zhong, Y.F., Wang, A.M., Su, J.K., Zhang, M.Q., 2013. Antinociceptive effect of berberine on visceral hypersensitivity in rats. World Journal of Gastroenterology: WJG, 19(28), 4582-4589.
44. Taylor, C.T., Winter, D.C., Skelly, M.M., O'Donoghue, D.P., O'Sullivan, G.C., Harvey, B.J., Baird, A.W., 1999. Berberine inhibits ion transport in human colonic epithelia. European Journal of Pharmacology, 368(1), 111-118.
45. Wang, Z.C., Wang, J., Chen, H., Tang, J., Bian, A.W., Liu, T., Yang, F., 2020. Synthesis and anticancer activity of novel 9, 13-disubstituted berberine derivatives. Bioorganic & Medicinal Chemistry Letters, 30(2), 126821.
46. Webb, A.N., Kukuruzovic, R., Catto‐Smith, A.G., Sawyer, S.M., 2007. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews, (4), CD005110.
47. Wu, D.Z., Yuan, J.Y., Shi, H.L., Hu, Z.B., 2008. Palmatine, a protoberberine alkaloid, inhibits both Ca2+‐and cAMP‐activated Cl− secretion in isolated rat distal colon. British Journal of Pharmacology, 153(6), 1203-1213.
48. Yan, F., Wang, L., Shi, Y., Cao, H., Liu, L., Washington, M.K., Polk, D.B., 2012. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. American Journal of Physiology-Gastrointestinal and Liver Physiology, 302(5), G504-G514.
49. Yin, J., Xing, H., Ye, J., 2008. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57(5), 712-717.
50. Yu, F., Ao, M., Zheng, X., Li, N., Xia, J., Li, Y., Chen, X.D., 2017. PEG–lipid–PLGA hybrid nanoparticles loaded with berberine–phospholipid complex to facilitate the oral delivery efficiency. Drug Delivery, 24(1), 825-833.
51. Yu, Z.C., Cen, Y.X., Wu, B.H., Wei, C., Xiong, F., Li, D.F., Yao, J., 2019. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats. World Journal of Gastroenterology, 25(29), 3956-3971.
52. Zhang, L.S., Zhang, J.H., Feng, R., Jin, X.Y., Yang, F.W., Ji, Z.C., Li, X.M., 2019. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. The American Journal of Chinese Medicine, 47(04), 751-767.
53. Zhang, M., Long, Y., Sun, Y., Wang, Y., Li, Q., Wu, H., Mei, Q., 2011. Evidence for the complementary and synergistic effects of the three-alkaloid combination regimen containing berberine, hypaconitine and skimmianine on the ulcerative colitis rats induced by trinitrobenzene-sulfonic acid. European Journal of Pharmacology, 651(1-3), 187-196.
54. Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Ning, G., 2008. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. The Journal of Clinical Endocrinology & Metabolism, 93(7), 2559-2565.
55. Zhou, H., Mineshita, S., 2000. The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics, 294(3), 822-829.